BG Medicine Inc., a Waltham, Mass.-based developer of molecular diagnostics based on biomarkers, has withdrawn its IPO registration, citing “unfavorable market conditions.” The company originally planned to raise up to $72 million, but later lowered its high mark to $45 million. Cowen & Co. was serving as lead underwriter.
BG Medicine has raised around $37 million in VC funding since 2000, from firms like Flagship Ventures (57.5% pre-IPO stake), Gilde Investment Management (17.4%) and Koniklijke Philips Electronics (8%).
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.